Potential Impact of Weight Loss Drugs in Rheumatic Diseases Dr. Arthur Kavanaugh highlights a session regarding weight loss and improvement in disease outcomes, specific weight loss drugs (SGL-2 and GLP-1), along with downsides when patients stop these medications. Reporting… https://t.co/Ilu2FXK2xi https://t.co/7CKSnfuey4

Yang et al. Cranial vessel wall MRI in GCA. Quantitated with PEG score. PEG score ocular GCA>non-ocular GCA>non-GCA. Decreases with treatment. @RheumNow #ACR24 Abstr#2650 https://t.co/e26urOpb7V https://t.co/eekQbzmKYm

• Extent of Vascular Inflammation on Cranial Vessel Wall MRI and Ophthalmic Compl…
• https://x.com/RichardPAConway/status/1858616166966497497/photo/1

A#2652 NEWTON study 🇫🇷 Retrosp cohort 51% relapse. Median @8.7 mos, dose 9mg pred Rf: limb art involv- HR 1.9 Pred taper speed not risk for relapse Most relapse -> incr GCs Toci 1/3 at dx, 50% stopped -61% d/c due to remission, 39% SEs -1/3 relapse after d/c @RheumNow #ACR24 https://t.co/NP0wieDmvo

• https://x.com/ericdeinmd/status/1858620704528146555/photo/1

Peyrac et al. 211 GCA. Relapse in 52% at median 261 days (so 1st year). 83% on GCs at relapse, median dose 6.5mg pred. 36% relapse post-toc discontinuation, at median 133 days. 64% no relapse when toc stopped, at median 511 days @RheumNow #ACR24 Abstr#2652 https://t.co/NqtdDNGGoc https://t.co/mXD8x7O6Ww

• You searched for Characteristics of Relapse and Therapeutic Management in Giant…
• https://x.com/RichardPAConway/status/1858621703745925264/photo/1

Study by Maria Dall'Era et al. compared voclosporin-based triple immunosuppressive therapy with high-dose GC in active lupus nephritis. - Fewer adverse events in the voclosporin group, despite a higher incidence of specific issues like decreased GFR and hypertension. - 25%… https://t.co/ToRu2rdErC https://t.co/uUXzNNuLDb

• https://x.com/i/web/status/1858608171926814731
• https://x.com/synovialjoints/status/1858608171926814731/photo/1

How do you manage DMARDs when giving the recombinant #zoster #vaccine (#RZV)? ➡️75 pts with ARDs 💉2-week #MTX discontinuation after each dose of RZV ⏩Significant boost in immune response without difference in flare rates Ab2612 #ACR24 @RheumNow https://t.co/o4iqj3e1Be

• https://x.com/DrMiniDey/status/1858609875758010555/photo/1

A#2650 MRI can show extent of vessel wall inflamm to guide severity of GCA Brain & orbital MRI performed Assessed 7 arteries bilaterally -> CAMRIS-GCA MRI score (0-10) 33 GCA (17 ocular), 41 not GCA CAMRIS-GCA ass w/ ocular GCA, higher severity. Improved w Rx @RheumNow #ACR24 https://t.co/19XCuZJXqF

• https://x.com/ericdeinmd/status/1858613190541631668/photo/1
• https://x.com/ericdeinmd/status/1858613190541631668/photo/1
• https://x.com/ericdeinmd/status/1858613190541631668/photo/1

A higher number of axSpA pts enrolled in BE MOBILE 1&2 who were treated with BKZ achieved remission accdg to the OSI vs. ASDAS ID (40.5% vs 15.2%) at wk 16 until wk 52. OSI a better measure of remission? @RheumNow #ACR24 abs2362 https://t.co/GCHjXQi9S9

• https://x.com/RHEUMarampa/status/1858595035559932201/photo/1

Medeiros-Ribeiro et al. Holding MTX for 2 weeks after recombinant zoster vaccine increases response with no increase in flare. @RheumNow #ACR24 Abstr#2612 https://t.co/NEop0XB5Ak https://t.co/P4S2qzbkTs

• Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients…
• https://x.com/RichardPAConway/status/1858606100754407799/photo/1

SmPCs recommend interrupting immunosuppression (IS) in infection What happens if you continue the drug? Ab2611 found no difference in infection outcomes btwn temp interruption & continuation of IS in infection Could continuation be a safe option in some pts? #ACR24 @RheumNow https://t.co/14SN6a4Wm8

• https://x.com/DrMiniDey/status/1858606604293468406/photo/1